Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide versus placebo in pediatric type 2 diabetes on metformin and/or basal insulin
2018-002952-34Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in glycosylated haemoglobin (HbA1c). Started Jul 2020; status: active.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2018-002952-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002952-34.